ANALISIS ABSOLUTE NEUTROPHIL COUNT DI PASIEN KANKER PAYUDARA DENGAN KEMOTERAPI

2016 ◽  
Vol 21 (3) ◽  
pp. 215
Author(s):  
Arifa Moidady ◽  
Tenri Esa ◽  
Uleng Bahrun
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Relative Number ◽  
Common Symptom ◽  
Breast Cancer Patients ◽  
Patient Age ◽  
Patient Âgé ◽  
The Absolute

The Absolute Neutrophil Count (ANC) is the absolute number of neutrophil derived from the multiplication of the relative number of leukocytes to the total neutrophil count. Neutrophils can be disturbed due to myelosupressive effects of chemotherapy. Fever is a common symptom in neutropenia patients due to chemotherapy. This fever is an emergency requiring rapid handling of Oncology and needs administration of appropriate antibiotics. Therefore, the data on the occurence of neutropenia and its related fever in patients whom accept chemotherapy after breast cancer it is important to be noted. This study is carried on to know the Absolute Neutrophil Count (ANC) in breast cancer patients with chemotherapy by analyzing them. The study was performed retrospectively by taking medical record data from January up to December 2012 in Dr. Wahidin Sudirohusodo Hospital Makassar. The absolute Neutrophil Count pre and afterchemotherapy analysis was done to determine neutropenia, as well as the febrile neutropenia and the correlation between ANC with patients age and stage of breast cancer. A total of 55 samples with the majority of patients (85.45%) were in the age group of 41–60 years old. The ANC after chemotherapy occurred in 50 patients were decreased (90.91%). There are five (5) patients (9.09%) with fever and two (2) persons (patients) (3.63%) suffered febrile neutropenia. The correlation analysis between decreased ANC with patient age and stage of breast cancer are p=0.054 and 0.070 respectively. Based on this study it can be concluded, that decreased ANC occurredin most patients after accepting chemotherapy but only few patients suffered febrile neutropenia. There was no significant correlation between the decreased ANC with patient age and stage of breast cancer

scholarly journals ANALISIS ABSOLUTE NEUTROPHIL COUNT DI PASIEN KANKER PAYUDARA DENGAN KEMOTERAPI (Analysis of Absolute Neutrophil Count in Breast Cancer Patients with Chemotherapy)

2018 ◽  
Vol 21 (3) ◽  
pp. 215
Author(s):  
Arifa Moidady ◽  
Tenri Esa ◽  
Uleng Bahrun
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Relative Number ◽  
Absolute Number ◽  
Age Group ◽  
Breast Cancer Patients ◽  
The Absolute

The Absolute Neutrophil Count (ANC) is the absolute number of neutrophil derived from the multiplication of the relative number ofleukocytes to the total neutrophil count. Neutrophils can be disturbed due to myelosupressive effects of chemotherapy. Fever is a commonsymptom in neutropenia patients due to chemotherapy. This fever is an emergency requiring rapid handling of Oncology and needsadministration of appropriate antibiotics. Therefore, the data on the occurence of neutropenia and its related fever in patients whomaccept chemotherapy after breast cancer it is important to be noted. This study is carried on to know the Absolute Neutrophil Count(ANC) in breast cancer patients with chemotherapy by analyzing them. The study was performed retrospectively by taking medical recorddata from January up to December 2012 in Dr. Wahidin Sudirohusodo Hospital Makassar. The absolute Neutrophil Count pre and afterchemotherapy analysis was done to determine neutropenia, as well as the febrile neutropenia and the correlation between ANC withpatients age and stage of breast cancer. A total of 55 samples with the majority of patients (85.45%) were in the age group of 41–60years old. The ANC after chemotherapy occurred in 50 patients were decreased (90.91%). There are five (5) patients (9.09%) with feverand two (2) persons (patients) (3.63%) suffered febrile neutropenia. The correlation analysis between decreased ANC with patient ageand stage of breast cancer are p=0.054 and 0.070 respectively. Based on this study it can be concluded, that decreased ANC occurredin most patients after accepting chemotherapy but only few patients suffered febrile neutropenia. There was no significant correlationbetween the decreased ANC with patient age and stage of breast cancer.

Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 671-671
Author(s):  
K. T. Vance ◽  
J. Carpenter
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Bone Pain ◽  
Common Side Effect ◽  
Breast Cancer Patients ◽  
Dose Dense

671 Background: Pegfilgrastim is indicated to decrease the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. In licensing studies, patients received a single dose of pegfilgrastim on day 2 of each chemotherapy cycle, which added an extra visit for day 2 administration. We administered pegfilgrastim to a series of early breast cancer patients on the same day of chemotherapy. We reviewed charts retrospectively to assess both efficacy and safety. Methods: Data on blood counts, toxicity and chemotherapy dosing was collected from July 1, 2003 to May 6, 2005 for all patients with early breast cancer who received sequential or combination doxorubicin, cyclophosphamide and paclitaxel on a 14 day schedule. Herceptin was given with paclitaxel and/or cyclophosphamide in 2 patients. Results: 64 patients with a median age of 50 years (range 22–67 years) were treated. 14 patients had stage I disease, 39 stage II and 11 stage III disease. Forty-one patients were treated postoperatively and 23 preoperatively. 211 cycles of doxorubicin were administered. After administration of doxorubicin, pegfilgrastim 6 mg s.c. was given on the same day. The lowest absolute neutrophil count on day 14 after doxorubicin was 1693/mm3 with no episodes of febrile neutropenia. The highest absolute neutrophil count was 23,671/mm3. The only dose reductions were five doxorubicin doses for grade 1–2 mucositis. Grade 1–2 nausea and vomiting was the most common toxicity seen after doxorubicin. Grade 1 bone pain was the most common side effect seen after pegfilgrastim occurring in 13/64 patients. There was no grade 3 or 4 toxicity of any kind. Conclusion: Pegfilgrastim administered on the same day as doxorubicin on a 14 day schedule was both safe and effective. Side effects were mild and included bone pain most likely attributable to pegfilgrastim. Neither granulocytopenia nor febrile neutropenia were seen and no treatments were delayed or postponed. Pegfilgrastim given on the same day as chemotherapy was effective in maintaining adequate granulocyte counts to allow treatment 14 days later and to avoid infection from granulocytopenia. Toxicity from pegfilgrastim was mild and tolerable. [Table: see text]

scholarly journals Kanker Payudara Pasca Kemoterapi dengan Neutropenia: Laporan Kasus

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Anita Rahmawati ◽  
Pearla Lasut
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Clinical Features ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Solid Tumor ◽  
Hematological Malignancy ◽  
Chemotherapy Patients

Abstract: Febrile neutropenia is found in 10-50% of post chemotherapy patients with solid tumor and in more than 80% of patients with hematological malignancy. We reported a case of febrile neutropenia, local chemoport infection, and right breast cancer on chemoterapy in a 47-year-old female. Diagnosis was based on symptoms, clinical features, and laboratory examina-tion with absolute neutrophil count (ANC) 460 cells/mm3. This patient was treated with IVFD NaCl 0.9% 20 drops/minute, ceftazidime 2 g every 8 hour intravenous, and filgastrim 300 mcg every 24 hours subcutan. The prognosis of this patient was as follows: ad vitam was dubia ad malam, ad functionam was dubia ad bonam, and ad sanationam was dubia.Keywords: febrile neutropenia, post chemotherapy Abstrak: Febrile neutropenia terjadi pada 10-50% pasien pasca kemoterapi dengan tumor padat dan lebih dari 80% pasien pasca kemoterapi dengan keganasan hematologik. Kami melaporkan sebuah kasus seorang perempuan berusia 47 tahun dengan febrile neutropenia, infeksi lokal chemoport, dan kanker payudara on kemoterapi. Diagnosis ditegakkan berdasarkan anamnesis, gejala dan tanda klinis, serta pemeriksaan laboratorium absolute neutrophil count (ANC) 460 sel/mm3. Pasien diberikan terapi infus NaCl 0,9% 20 tetes/menit, ceftazidime injeksi 2 gr setiap 8 jam, dan filgastrim injeksi 300 mcg setiap 24 jam subkutan. Prognosis pasien ini secara ad vitam ialah dubia ad malam, ad functionam ialah dubia ad bonam, dan ad sanationam ialah dubia.Kata kunci: febrile neutropenia, pasca kemoterapi

Predictive factors of adjuvant therapy-related amenorrhea for patients with breast cancer.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 217-217
Author(s):  
N. Tamura ◽  
T. Kato ◽  
C. Shimizu ◽  
T. Kinoshita ◽  
Y. Fujiwara
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Intrinsic Subtype ◽  
Reproductive Age ◽  
Breast Cancer Patients ◽  
Patient Age ◽  
Logistic Analysis ◽  
Patient Âgé ◽  
Number Of Patients ◽  
The Mean

217 Background: Reproductive age breast cancer patients often experience therapy-related amenorrhea so preserving fertility after treatment is a major concern. Anti-mullerian hormone (AMH) values have been reported useful in predicting menopause for infertility treatment patients, but published information is limited regarding breast cancer patients. If amenorrhea can be predicted before treatment, breast cancer patients hoping to have children in the future can consider this information in choosing treatment. Our aim was to predict patient fertility using AMH values. Methods: Forty breast cancer patients, 25-45 years of age (median, 35.5), who received adjuvant chemotherapy (CT) or endocrine therapy (ET), had AMH values retrospectively assayed from frozen serum before and after treatment. AMH values were then analyzed in relation to clinicopathological factors using logistic analysis. Of 19 adjuvant CT patients whose AMH values could be assayed, Cox’s proportional hazard model indicated a correlation in terms of amenorrhea and time to menses resumption between clinicolpathological factors and AMH values. Results: The mean pretreatment AMH value for all 40 patients was 21.4pM (range, 3-78) and a correlation was demonstrated with patient age, but not breast cancer intrinsic subtype or stage. AMH values decreased to the lower limit after treatment for all CT patients regardless of age, but there was a difference in degree depending on patient age for ET patients. Of the 19 CT patients, the mean AMH value was 25.6pM (3-78). These patients all underwent a regimen of anthracycline with 11 (58%) also receiving a regimen of taxiane. After starting CT, 17 patients (89%) experienced amenorrhea, but 11 (59%) resumed menstruation within one year of finishing CT and 15 (78%) resumed within two years. There were no significant differences among CT patients in age, pretreatment AMH value, intrinsic subtype or stage, but patients receiving taxiane demonstrated a noteworthy trend. Conclusions: Although we were unable to predict menopause directly using AMH values given the small number of patients in this study, we could estimate the risk of menopause as being either low or high for CT patients based on age and type of regimen.

scholarly journals Association of ATP-binding cassette sub-family B member 1 gene C3435T polymorphism with neutropenia in breast cancer patients treated with chemotherapy

2016 ◽  
Vol 25 (3) ◽  
pp. 156-62 ◽  
Author(s):  
Siti Syarifah ◽  
Kamal B. Siregar ◽  
Yahwardiah Siregar
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Common Adverse Event ◽  
Wilcoxon Test ◽  
Atp Binding ◽  
Breast Cancer Patients ◽  
C3435t Polymorphism ◽  
Atp Binding Cassette

Background: Neutropenia is the most common adverse event of breast cancer chemotherapy which can be life threatening due to opportunistic infection, neutropenic episodes may lead to delay or reduction of drug doses which may compromise treatment outcomes. In this study, we investigated the association of ATP-binding cassette sub-family B member 1 (ABCB1) gene C3435T polymorphism with the grading of neutropenia in breast cancer patients who treated with doxorubicin-taxan.Methods: 72 Indonesian female breast cancer patients from Haji Adam Malik Hospital who had been diagnosed and treated with doxorubicin-taxane regimen were selected for this cohort study. DNA was extracted from peripheral leucocytes and ABCB1 C3435T polymorphism was analyzed with PCR-RFLP. Patient data were collected from patient’s medical record for 3 cycles of chemotherapy. Association between ABCB1 C3435T polymorphism with neutropenia was assessed using Kruskal-Wallis test. Decline of absolute neutrophil count was assessed using Wilcoxon test. Genotype deviation and allele frequencies were also determined by Hardy-Weinberg Equilibrium.Results: The frequencies of ABCB1 C3435T genotype for wildtype (CC), heterozygous (CT) and homozygous mutant (TT) was 22 (30.6%), 38 (52.8%) and 12 (16.7%) respectively. No association were found between ABCB1 C3435T polymorphism and the grading of neutropenia (p>0.05). There was a difference on the average of absolute neutrophil count after the first chemotherapy and after the third chemotherapy (p<0.05). There was no significant deviation of allele and genotype frequency from Hardy-Weinberg Equilibrium.Conclusion: ABCB1 C3435T polymorphism had no association with the grading of neutropenia in breast cancer patients treated with doxorubicin-taxane regimen, however there was a trend of absolute neutrophil count declining during the 3 cycles of chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document